Benchmark Genetics chief steps down
Melingen decision 'reflects a personal career step'
Salmon ova supplier Benchmark Genetics today announced that Geir Olav Melingen has decided to resign from his position as chief executive. He will remain in the company for a transition period to support a smooth handover to the next CEO.
Benchmark Genetics, which was recently sold to Novo Holdings by Benchmark Holdings for £230 million, said Melingen had been with the Benchmark Group for six years, playing a key role in the growth of its aquaculture genetics business.
He was head of the genetics business area in Benchmark Holdings before being appointed CEO of Benchmark Genetics on April 1, 2025, following the company’s transition to independent ownership under Novo Holdings.
Novo Holdings, which is responsible for managing the assets and the wealth of Denmark's Novo Nordisk Foundation, said it has initiated the search process for a new CEO. In the interim, Aleks Engel, partner at Novo Holdings, will assume the role of interim CEO, supported by a dedicated team from Novo Holdings.
A privilege
“It has been a privilege to lead Benchmark Genetics through an exciting phase of growth and transition. I believe strongly in the company's future and the potential of its partnership with Novo Holdings,” said Melingen in a press release. “This decision reflects a personal career step, and I remain fully committed to ensuring a seamless transition in the period ahead.”
Benchmark Genetics said that under Melingen’s leadership, it has reinforced its position as a global leader in aquaculture genetics, providing high-quality genetic solutions to salmon, shrimp, and genetic programmes worldwide.
“Geir Olav has played a central role in building Benchmark Genetics into a strong and focused organisation with a clear strategic direction,” said Engel. “On behalf of Novo Holdings and the Board, I want to thank him for his leadership and dedication, and we look forward to working closely with the team during this transition.”
